PubRank

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

Clinical Trial ID NCT02082977

PubWeight™ 21.83‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02082977

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting EZH2 in cancer. Nat Med 2016 1.51
2 EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Stem Cell Reports 2015 1.13
3 Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med 2015 1.04
4 Selective inhibitors of protein methyltransferases. J Med Chem 2014 1.01
5 Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene 2015 1.00
6 Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell 2016 0.98
7 Chemical probes of histone lysine methyltransferases. ACS Chem Biol 2014 0.95
8 Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenetics 2016 0.95
9 Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer 2016 0.93
10 Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget 2015 0.92
11 Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies. Mod Pathol 2016 0.90
12 Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev 2015 0.88
13 EZH2 in Bladder Cancer, a Promising Therapeutic Target. Int J Mol Sci 2015 0.85
14 Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discov 2016 0.84
15 Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma. Lab Invest 2015 0.84
16 Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab Rev 2015 0.83
17 Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget 2015 0.83
18 Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Mol Cell 2015 0.81
19 Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention. Curr Opin Oncol 2015 0.79
20 Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment. World J Clin Oncol 2016 0.78
21 Epigenetic Medicinal Chemistry. ACS Med Chem Lett 2015 0.77
22 Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics 2016 0.76
23 Developing EZH2-Targeted Therapy for Lung Cancer. Cancer Discov 2016 0.75
24 Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors. J Med Chem 2016 0.75
25 Epigenetic dysregulation in follicular lymphoma. Epigenomics 2015 0.75
Next 100